BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32772754)

  • 21. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
    Chang VY; Wang JJ
    Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
    Armenian SH
    Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
    Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GSTM1 null variant associated with anthracycline-related cancer in pediatric cancer.
    Rassekh SR
    Cancer; 2020 Sep; 126(17):3926-3928. PubMed ID: 32413168
    [No Abstract]   [Full Text] [Related]  

  • 25. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
    Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
    Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
    Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
    Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
    Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
    Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
    Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
    BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.
    Berkman AM; Hildebrandt MAT; Landstrom AP
    Clin Genet; 2021 Aug; 100(2):132-143. PubMed ID: 33871046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of anthracycline-induced cardiotoxicity in a retro-prolective cohort of children surviving cancer.
    Rivas-Ruiz R; Ureña-Wong K; Castelán-Martínez OD; Betanzos-Cabrera Y; Lazo-Cárdenas C; Ramírez-Portillo C; López-Aguilar E
    Gac Med Mex; 2020; 156(3):217-223. PubMed ID: 32539021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline associated cardiotoxicity in survivors of childhood cancer.
    Lipshultz SE; Alvarez JA; Scully RE
    Heart; 2008 Apr; 94(4):525-33. PubMed ID: 18347383
    [No Abstract]   [Full Text] [Related]  

  • 36. Intrauterine Growth Retardation is a Risk Factor for Anthracycline Toxicity.
    Eroglu N; Yoldas T; Bilgin B; Yesil S; Fettah A; Sahin G
    Pediatr Hematol Oncol; 2021 Aug; 38(5):497-503. PubMed ID: 33715575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
    Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
    Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
    Dionne F; Aminkeng F; Bhavsar AP; Groeneweg G; Smith A; Visscher H; Rassekh SR; Ross C; Carleton B
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29271558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.
    Ding Y; Du K; Niu YJ; Wang Y; Xu X
    Oxid Med Cell Longev; 2022; 2022():5818612. PubMed ID: 35965684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.